TY - JOUR
T1 - Outcomes after Successful Percutaneous Coronary Intervention of Calcified Lesions Using Rotational Atherectomy, Cutting-Balloon Angioplasty, or Balloon-Only Angioplasty before Drug-Eluting Stent Implantation
AU - Redfors, Björn
AU - Maehara, Akiko
AU - Witzenbichler, Bernhard
AU - Weisz, Giora
AU - Stuckey, Thomas D.
AU - Henry, Timothy D.
AU - McAndrew, Thomas
AU - Mehran, Roxana
AU - Kirtane, Ajay J.
AU - Stone, Gregg W.
AU - Généreux, Philippe
N1 - Funding Information:
Disclosures: The authors have completed and returned the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Maehara reports grant support from Boston Scientific, St. Jude Medical; consultant fees from Boston Scientific, OCT Medical Imaging; speaker fees from St. Jude Medical. Dr Witzenbichler reports consultant fees from Volcano. Dr Weisz reports advisory board fees from AngioS-lide, AstraZeneca, Corindus, Filterlex, M.I. Medical Incentive, Medtronic, Medivi-zor, TriSol, and Vectorious. Dr Stuckey reports advisory board fees from Boston Scientific; speaker honoraria from Boston Scientific, Eli Lilly/Daiichi-Sankyo. Dr Henry reports scientific advisory board fees from Abbott Vascular, Boston Scientific, and The Medicines Company; steering committee for TRANSLATE (sponsored by Eli Lilly and Daiichi Sankyo). Dr Mehran reports institutional research grant support from Eli Lilly/Daiichi-Sankyo, Inc, Bristol-Myers Squibb, AstraZen-eca, The Medicines Company, OrbusNeich, Bayer, CSL Behring, Abbott Laboratories, Watermark Research Partners, Novartis Pharmaceuticals, Medtronic, AUM Cardiovascular, Inc, Beth Israel Deaconess Medical Center; executive committee for Janssen Pharmaceuticals, Osprey Medical, Inc; data safety monitoring board for Watermark Research Partners; consulting fees from Medscape, The Medicines Company, Boston Scientific, Merck & Company, Cardiovascular Systems, Inc (CSI), Sanofi USA, Shanghai BraccoSine Pharmaceutical Corp, AstraZeneca; equity in Claret Medical, Inc, Elixir Medical Corporation. Dr Kirtane reports institutional research grants to Columbia University from Boston Scientific, Medtronic, Abbott Vascular, Abiomed, St. Jude Medical, Vascular Dynamics, and Eli Lilly. Dr Généreux reports speaker’s fees from Abbott Vascular and Edwards Lifescienc-es; consulting fees from CSI, PiCardia, Soundbite Medical Solutions; institutional research grants from Boston Scientific, Tryton Medical.
PY - 2017/11
Y1 - 2017/11
N2 - OBJECTIVES: To report adverse event rates after rotational atherectomy (RA) with contemporary drug-eluting stent (DES) implantation and compare RA to cutting balloon (CB) angioplasty and balloon-only angioplasty (BA) in the all-comers ADAPT-DES trial. BACKGROUND: Percutaneous coronary intervention (PCI) of calcified lesions is increasingly common and is associated with a high risk of adverse events. RA can ablate calcified plaque and facilitate stent delivery; however, in conjunction with first-generation DES, RA was not superior to BA alone in regard to adverse events. METHODS: ADAPT-DES enrolled 8582 patients who underwent successful PCI with DES, of whom 2644 had calcified target lesions and were included in this study. Among these patients, 1610 had exclusively second-generation DESs implanted. We present Kaplan-Meier rates for the primary endpoint of target-vessel failure (TVF; defined as death, myocardial infarction, or target-vessel revascularization) as well as its components, for patients who had RA, CB, or BA. RESULTS: Among the 2644 patients, RA and CB were used in 150 patients (5.7%) and 53 patients (2.0%), respectively. TVF occurred in 20.8% of the RA patients, 24.1% of the CB patients, and 17.9% of the BA patients over the 2-year study period (P≤.41) and was primarily driven by target-vessel revascularization (13.8%, 11.4%, and 10.2%, respectively). RA patients with acute coronary syndromes had nominally higher 2-year TVF rates than RA patients with stable coronary artery disease. CONCLUSION: TVF is common after contemporary DES-PCI of calcified lesions, independent of the technique used to prepare the vessel for stent implantation. Better treatment strategies are needed.
AB - OBJECTIVES: To report adverse event rates after rotational atherectomy (RA) with contemporary drug-eluting stent (DES) implantation and compare RA to cutting balloon (CB) angioplasty and balloon-only angioplasty (BA) in the all-comers ADAPT-DES trial. BACKGROUND: Percutaneous coronary intervention (PCI) of calcified lesions is increasingly common and is associated with a high risk of adverse events. RA can ablate calcified plaque and facilitate stent delivery; however, in conjunction with first-generation DES, RA was not superior to BA alone in regard to adverse events. METHODS: ADAPT-DES enrolled 8582 patients who underwent successful PCI with DES, of whom 2644 had calcified target lesions and were included in this study. Among these patients, 1610 had exclusively second-generation DESs implanted. We present Kaplan-Meier rates for the primary endpoint of target-vessel failure (TVF; defined as death, myocardial infarction, or target-vessel revascularization) as well as its components, for patients who had RA, CB, or BA. RESULTS: Among the 2644 patients, RA and CB were used in 150 patients (5.7%) and 53 patients (2.0%), respectively. TVF occurred in 20.8% of the RA patients, 24.1% of the CB patients, and 17.9% of the BA patients over the 2-year study period (P≤.41) and was primarily driven by target-vessel revascularization (13.8%, 11.4%, and 10.2%, respectively). RA patients with acute coronary syndromes had nominally higher 2-year TVF rates than RA patients with stable coronary artery disease. CONCLUSION: TVF is common after contemporary DES-PCI of calcified lesions, independent of the technique used to prepare the vessel for stent implantation. Better treatment strategies are needed.
KW - PCI
KW - major adverse cardiac events
KW - rotational atherectomy
KW - second-generation drug-eluting stent
UR - http://www.scopus.com/inward/record.url?scp=85032265683&partnerID=8YFLogxK
M3 - Article
C2 - 28623669
AN - SCOPUS:85032265683
SN - 1042-3931
VL - 29
SP - 378
EP - 386
JO - Journal of Invasive Cardiology
JF - Journal of Invasive Cardiology
IS - 11
ER -